Mode
Text Size
Log in / Sign up
N/A N=175 Treatment

Non-Invasive Cooling of Fat Cells

Reduction of Unwanted Fat

Enrolled (actual)
175
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Percentage of Participants With Visible Improvement in Treated Area — 65.2; 82.8 percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Zeltiq Dermal Cooling Device (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Zeltiq Aesthetics
Primary completion
Nov 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Visible Improvement in Treated Area
65.2; 82.8
SECONDARY
Participant Satisfaction
51.4; 58.5; 8.1; 6.2; 32.4; 35.4

Summary

The purpose of this study is to evaluate a non-invasive cooling device to determine if cold exposure will consistently result in a reduction of subcutaneous fat.

Eligibility Criteria

Inclusion Criteria

  • Male or female subjects > 18 years of age.
  • Subject has clearly visible fat on an area of the body appropriate for treatment with the non-invasive Zeltiq cooling device such as the flanks, thighs, abdomen or back.
  • Subject has not had weight change fluctuations exceeding 10 pounds in the preceding month and plans to maintain their weight to within ±10 pounds over the next 6 months.
  • Subject has read and signed a written informed consent form.

Exclusion Criteria

  • Subject has had liposuction, or another surgical procedure(s) or mesotherapy in area of intended treatment within the past 2 years.
  • Subject has a known history of subcutaneous injections into the area of intended treatment (e.g., cortisone) within the past 6 months.
  • Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.
  • Subject has used diet pills within the past 6 months.
  • Subject is unable or unwilling to comply with the study requirements.
  • Subject has any dermatological conditions or scars within the location of the test sites that may interfere with the treatment or evaluation.
  • Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
  • Patient is pregnant or intending to become pregnant in the next 9 months.
  • Patient is lactating or has been lactating in the past 9 months.
  • Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00762437). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search